Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL Presented ByDr Eugen Tausch, University of Ulm, Germany TrialCLL14 ConferenceEHA 2019 9 August, 2019 22:38
Venetoclax-obinutuzumab combination elicits high response rates in CLL Presented ByDr Kirsten Fischer, University of Cologne, Germany TrialPhase 3, CLL14 ConferenceEHA 2019 9 June, 2019 23:28